CXCR6 and hepatocellular carcinoma: Furthermore, anti–PD-1 therapy fails to reduce the tumor burden in preclinical models of MASH-related HCC and indeed results in the accumulation of CXCR6+PD1+CD8+ T cells [14], suggesting that these cells are likely responsible for the lack of responsiveness of MASH-related HCC to immune checkpoint inhibitors.